Tango Therapeutics draws fresh attention after $618,000 insider sale
Tango Therapeutics shares rose 1.8% to $21.86 Thursday after a filing showed research chief Adam Crystal sold 27,000 shares for about $617,571 under a preset plan. The company’s lead drug, vopimetostat, is in Phase 1/2 trials for MTAP-deleted cancers, with initial data expected in 2026. The SPDR S&P Biotech ETF gained 2.6%.